These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 32340606)

  • 1. Cryptococcal meningoencephalitis in an IgG
    Wienemann T; Müller AK; MacKenzie C; Bielor C; Weyers V; Aktas O; Hartung HP; Kremer D
    BMC Neurol; 2020 Apr; 20(1):158. PubMed ID: 32340606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis.
    Ward MD; Jones DE; Goldman MD
    Mult Scler Relat Disord; 2016 Sep; 9():47-9. PubMed ID: 27645342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings.
    Chong I; Wang KY; Lincoln CM
    Clin Imaging; 2019; 54():53-56. PubMed ID: 30544079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cryptococcus neoformans var grubii meningoencephalitis in a patient on fingolimod for relapsing-remitting multiple sclerosis: Case report and review of published cases.
    Ma SB; Griffin D; Boyd SC; Chang CC; Wong J; Guy SD
    Mult Scler Relat Disord; 2020 Jan; 39():101923. PubMed ID: 31986367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections?
    Carpenter AF; Goodwin SJ; Bornstein PF; Larson AJ; Markus CK
    Mult Scler; 2017 Feb; 23(2):297-299. PubMed ID: 28165320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cryptococcal meningoencephalitis in a multiple sclerosis patient after fingolimod discontinuation-a case report.
    Baghbanian SM; Amiri MRM
    Neurol Sci; 2021 Mar; 42(3):1175-1177. PubMed ID: 32968870
    [No Abstract]   [Full Text] [Related]  

  • 7. Necrotizing fungal osteomyelitis and fingolimod, 4 years after treatment with fingolimod.
    Harirchian MH; Poursadeghfard M; Sadeghipour A; Kamali H; Sarraf P
    Mult Scler Relat Disord; 2020 Jun; 41():102021. PubMed ID: 32126512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: A case report and review of literature.
    Grebenciucova E; Reder AT; Bernard JT
    Mult Scler Relat Disord; 2016 Sep; 9():158-62. PubMed ID: 27645366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disseminated Cryptococcosis in a 63-year-old Patient with Multiple Sclerosis Treated with Fingolimod.
    Seto H; Nishimura M; Minamiji K; Miyoshi S; Mori H; Kanazawa K; Yasuda H
    Intern Med; 2016; 55(22):3383-3386. PubMed ID: 27853088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fingolimod-related cryptococcal meningoencephalitis and immune reconstitution inflammatory syndrome in a patient with multiple sclerosis.
    Cuascut FX; Alkabie S; Hutton GJ
    Mult Scler Relat Disord; 2021 Aug; 53():103072. PubMed ID: 34139459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cryptococcal Meningoencephalitis in a Patient With Multiple Sclerosis Treated With Fingolimod.
    Achtnichts L; Obreja O; Conen A; Fux CA; Nedeltchev K
    JAMA Neurol; 2015 Oct; 72(10):1203-5. PubMed ID: 26457631
    [No Abstract]   [Full Text] [Related]  

  • 12. Improvement of macular edema without discontinuation of fingolimod in a patient with multiple sclerosis: A case report.
    Akiyama H; Suzuki Y; Hara D; Shinohara K; Ogura H; Akamatsu M; Hasegawa Y
    Medicine (Baltimore); 2016 Jul; 95(29):e4180. PubMed ID: 27442641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis.
    Izquierdo G; O'Connor P; Montalban X; von Rosenstiel P; Cremer M; de Vera A; Sfikas N; Francis G; Radue EW; Kappos L
    Mult Scler; 2014 Jun; 20(7):877-81. PubMed ID: 24293455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study.
    Ordoñez-Boschetti L; Rey R; Cruz A; Sinha A; Reynolds T; Frider N; Alvarenga R
    Adv Ther; 2015 Jul; 32(7):626-35. PubMed ID: 26170105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approach to Fingolimod-Induced Lymphopenia in Multiple Sclerosis Patients: Do We Have a Roadmap?
    Avasarala J; Jain S; Urrea-Mendoza E
    J Clin Pharmacol; 2017 Nov; 57(11):1415-1418. PubMed ID: 28543950
    [No Abstract]   [Full Text] [Related]  

  • 16. Ventricular tachycardia after initiation of fingolimod.
    Elounais F; Aburahma A; Alkotob ML; Al Hadidi S
    BMJ Case Rep; 2017 Sep; 2017():. PubMed ID: 28954755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Infections and fingolimod].
    Cervera C
    Rev Neurol; 2012 Aug; 55(4):227-37. PubMed ID: 22829086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypothyroidism in multiple sclerosis patient during fingolimod treatment.
    Flores J; Rito Y; Torres G; Jung H; Treviño-Frenk I; Corona T
    J Neurol Sci; 2015 Jan; 348(1-2):272-3. PubMed ID: 25491264
    [No Abstract]   [Full Text] [Related]  

  • 19. Disseminated tuberculosis associated with fingolimod treatment in a patient with multiple sclerosis.
    Ong S; Kibbler J; Maxwell G; Steer J
    BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38171639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aggressive cutaneous leishmaniasis in a patient with multiple sclerosis treated with fingolimod.
    Hernández Clares R; Sánchez Pedreño P; García Vazquez E; Carreón Guarnizo E; Meca Lallana JE
    Neurologia (Engl Ed); 2018 Jun; 33(5):348-349. PubMed ID: 28535923
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.